These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Induction of metallothionein in chick embryos as a mechanism of tolerance to platinum group metal exposure. Gagnon ZE; Patel A J Environ Sci Health A Tox Hazard Subst Environ Eng; 2007 Feb; 42(3):381-7. PubMed ID: 17365305 [TBL] [Abstract][Full Text] [Related]
23. Interactions of cis-platinum with cellular zinc and copper in rat liver and kidney tissues. Sharma RP Pharmacol Res Commun; 1985 Feb; 17(2):197-206. PubMed ID: 4039454 [TBL] [Abstract][Full Text] [Related]
24. A phase I trial of the oral platinum analogue JM216 with concomitant radiotherapy in advanced malignancies of the chest. George CM; Haraf DJ; Mauer AM; Krauss SA; Hoffman PC; Rudin CM; Szeto L; Vokes EE Invest New Drugs; 2001; 19(4):303-10. PubMed ID: 11561689 [TBL] [Abstract][Full Text] [Related]
25. DNA-binding properties of novel cis- and trans platinum-based anticancer agents in 2 human ovarian carcinoma cell lines. Mellish KJ; Barnard CF; Murrer BA; Kelland LR Int J Cancer; 1995 Sep; 62(6):717-23. PubMed ID: 7558420 [TBL] [Abstract][Full Text] [Related]
26. Interaction of metallothionein-2 with platinum-modified 5'-guanosine monophosphate and DNA. Karotki AV; Vasák M Biochemistry; 2008 Oct; 47(41):10961-9. PubMed ID: 18803406 [TBL] [Abstract][Full Text] [Related]
27. Validation of an AAS method for the determination of platinum in biological fluids from patients receiving the oral platinum derivative JM216. Vouillamoz-Lorenz S; Bauer J; Lejeune F; Decosterd LA J Pharm Biomed Anal; 2001 Jun; 25(3-4):465-75. PubMed ID: 11377026 [TBL] [Abstract][Full Text] [Related]
28. Potent and non-specific inhibition of cytochrome P450 by JM216, a new oral platinum agent. Ando Y; Shimizu T; Nakamura K; Mushiroda T; Nakagawa T; Kodama T; Kamataki T Br J Cancer; 1998 Nov; 78(9):1170-4. PubMed ID: 9820175 [TBL] [Abstract][Full Text] [Related]
29. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin. O'Neill CF; Koberle B; Masters JR; Kelland LR Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725 [TBL] [Abstract][Full Text] [Related]
30. Organ distribution and tumor uptake of liposome entrapped cis-bis-neodecanoato trans-R, R-1,2 diaminocyclohexane platinum (II) administered intravenously and into the proper hepatic artery. Khokhar AR; Wright K; Siddik ZH; Perez-Soler R Cancer Chemother Pharmacol; 1988; 22(3):223-7. PubMed ID: 3409456 [TBL] [Abstract][Full Text] [Related]
31. Hepatic and renal metallothionein induction by an oral equimolar dose of zinc, cadmium or mercury in mice. Tandon SK; Singh S; Prasad S; Mathur N Food Chem Toxicol; 2001 Jun; 39(6):571-7. PubMed ID: 11346487 [TBL] [Abstract][Full Text] [Related]
32. Metabolic studies of an orally active platinum anticancer drug by liquid chromatography-electrospray ionization mass spectrometry. Poon GK; Raynaud FI; Mistry P; Odell DE; Kelland LR; Harrap KR; Barnard CF; Murrer BA J Chromatogr A; 1995 Sep; 712(1):61-6. PubMed ID: 8556156 [TBL] [Abstract][Full Text] [Related]
33. The tissue distribution in BALB/c mice of C-14-labeled JM216, an orally active platinum antitumour compound. Bates PI; Sharma HL; Murrer BA; McAuliffe CA Cancer Chemother Pharmacol; 1996; 39(1-2):170-5. PubMed ID: 8995517 [TBL] [Abstract][Full Text] [Related]
34. Hepatic zinc response via metallothionein induction after tumor transplantation. Tamano H; Igasaki E; Enomoto S; Oku N; Itoh N; Kimura T; Tanaka K; Takeda A Biochem Biophys Res Commun; 2000 Apr; 270(3):1140-3. PubMed ID: 10772964 [TBL] [Abstract][Full Text] [Related]
35. The synthesis of metallothionein-like protein containing zinc in liver of rat after administration of calcium and calcitonin. Miyahara T; Nemoto S; Kaji T; Yamada H; Takeuchi M; Mori M; Kozuka H Toxicol Lett; 1986 May; 31(2):113-23. PubMed ID: 3715922 [TBL] [Abstract][Full Text] [Related]
36. Mechanisms of regulation of rat hepatic metallothionein-I and metallothionein-II levels following administration of zinc. Lehman-McKeeman LD; Andrews GK; Klaassen CD Toxicol Appl Pharmacol; 1988 Jan; 92(1):1-9. PubMed ID: 3341018 [TBL] [Abstract][Full Text] [Related]
37. Preclinical toxicology and tissue platinum distribution of novel oral antitumour platinum complexes: ammine/amine platinum(IV) dicarboxylates. McKeage MJ; Morgan SE; Boxall FE; Murrer BA; Hard GC; Harrap KR Cancer Chemother Pharmacol; 1994; 33(6):497-503. PubMed ID: 8137461 [TBL] [Abstract][Full Text] [Related]
38. Metallothionein, zinc, and mercury levels in tissues of young rats exposed to zinc and subsequently to mercury. Peixoto NC; Serafim MA; Flores EM; Bebianno MJ; Pereira ME Life Sci; 2007 Sep; 81(16):1264-71. PubMed ID: 17916369 [TBL] [Abstract][Full Text] [Related]
39. Effect of zinc supplementation on metallothionein, copper, and zinc concentration in various tissues of copper-loaded rats. Irato P; Sturniolo GC; Giacon G; Magro A; D'Inca R; Mestriner C; Albergoni V Biol Trace Elem Res; 1996 Jan; 51(1):87-96. PubMed ID: 8834384 [TBL] [Abstract][Full Text] [Related]
40. Different accumulation of cisplatin, oxaliplatin and JM216 in sensitive and cisplatin-resistant human cervical tumour cells. Martelli L; Di Mario F; Ragazzi E; Apostoli P; Leone R; Perego P; Fumagalli G Biochem Pharmacol; 2006 Sep; 72(6):693-700. PubMed ID: 16844093 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]